来源：新浪证券-红岸工作室 2、根据2024年年报，公司海外营收占比为62.85%，受益于人民币贬值。 创新药+人民币贬值受益 1、2025年6月13日互动易：公司是一家全球领先的肿瘤创新治疗公司，为全世界癌症患者研发创新抗肿 瘤药物，提升药物可及性和可负担性。 区间今日近3日近5日近10日近20日主力净流入-1725.95万-1.06亿-1.01亿-2.03亿-4.70亿 主力持仓 2月3日，百济神州涨1.64%，成交额6.51亿元，换手率2.08%，总市值4212.21亿元。 异动分析 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-1725.95万，占比0.03%，行业排名145/158，连续3日被主力资金减仓；所属行业主力净 流入1.41亿，当前无连续增减仓现象，主力趋势不明显。 该股筹码平均交易成本为290.91元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位273.67，谨 防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10 ...

1月22日，百济神州跌1.77%，成交额5.83亿元。两融数据显示，当日百济神州获融资买入额5186.56万 元，融资偿还4397.53万元，融资净买入789.03万元。截至1月22日，百济神州融资融券余额合计8.71亿 元。 机构持仓方面，截止2025年9月30日，百济神州十大流通股东中，中欧医疗健康混合A（003095）位居 第四大流通股东，持股467.88万股，相比上期减少14.66万股。香港中央结算有限公司位居第五大流通股 东，持股315.65万股，为新进股东。万家优选（161903）位居第六大流通股东，持股250.00万股，相比 上期减少50.00万股。永赢医药创新智选混合发起A（015915）位居第八大流通股东，持股213.36万股， 为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东，持股200.00万股，相比上期减少 70.00万股。南方中证500ETF（510500）位居第十大流通股东，持股166.44万股，相比上期减少6.16万 股。 融资方面，百济神州当日融资买入5186.56万元。当前融资余额8.64亿元，占流通市值的2.61%，融资余 额低于近一年40%分位水平，处于较 ...

Core Viewpoint - The company, BeiGene, is a leading global innovator in cancer treatment, focusing on developing innovative anti-tumor drugs to enhance accessibility and affordability for cancer patients [2]. Financial Performance - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21% [7]. - The net profit attributable to the parent company was 1.139 billion yuan, showing a significant year-on-year increase of 130.88% [7]. - As of September 30, 2024, overseas revenue accounted for 62.85% of the total revenue, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On December 31, BeiGene's stock price decreased by 1.25%, with a trading volume of 358 million yuan and a turnover rate of 1.15%, resulting in a total market capitalization of 413.826 billion yuan [1]. - The main capital flow showed a net outflow of 54.6938 million yuan for the day, with a continuous reduction in main capital over the past three days [4][5]. Shareholder Information - As of September 30, 2025, the number of shareholders for BeiGene was 36,200, an increase of 55.33% compared to the previous period [7]. - The average number of tradable shares per shareholder was 3,195, which decreased by 35.79% from the previous period [7]. - Notable changes in institutional holdings include a decrease in shares held by major shareholders such as China Europe Medical Health Mixed A and a new entry by Hong Kong Central Clearing Limited [8]. Technical Analysis - The average trading cost of BeiGene's shares is 287.32 yuan, with recent reductions in holdings, although the pace of reduction has slowed [6]. - The current stock price is near a support level of 267.83 yuan, which is critical for potential rebound; a drop below this level may trigger a downward trend [6].

融资方面，百济神州当日融资买入2720.51万元。当前融资余额9.94亿元，占流通市值的3.12%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，百济神州12月23日融券偿还3729.00股，融券卖出1945.00股，按当日收盘价计算，卖出金额 53.84万元；融券余量4.45万股，融券余额1232.47万元，超过近一年70%分位水平，处于较高位。 资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10月 28日，上市日期2021年12月15日，公司主营业务涉及研究、开发、生产以及商业化创新型药物。主营业 务收入构成为：药品销售收入99.10%，合作安排收入0.90%。 12月23日，百济神州涨0.92%，成交额4.11亿元。两融数据显示，当日百济神州获融资买入额2720.51万 元，融资偿还3739.89万元，融资净买入-1019.38万元。截至12月23日，百济神州融资融券余额合计 10.06亿元。 截至9月30日，百济神州股东户数3.62万，较上期增加55.33%；人均流通股3195股，较上期减少 35.79%。2025年1月-9月，百济神州实现营 ...

Core Insights - On November 12, BeiGene's stock rose by 5.62%, with a trading volume of 1.793 billion yuan [1] - As of November 12, BeiGene's total margin trading balance reached 1.332 billion yuan, indicating a high level of trading activity [1] Financing Summary - On November 12, BeiGene had a financing buy-in amount of 201 million yuan, while the financing repayment was 231 million yuan, resulting in a net financing outflow of 30.15 million yuan [1] - The current financing balance of 1.312 billion yuan accounts for 3.88% of the circulating market value, which is above the 90th percentile level over the past year [1] Securities Lending Summary - On November 12, BeiGene repaid 1,200 shares in securities lending and sold 2,015 shares, amounting to a selling value of 591,600 yuan based on the closing price [1] - The remaining securities lending balance is 66,600 shares, with a total value of 19.56 million yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is located in the Zhongguancun Life Science Park, Beijing [1] - The company's main business involves the research, development, production, and commercialization of innovative drugs, with 99.10% of revenue coming from drug sales and 0.90% from collaboration arrangements [1] Shareholder Information - As of September 30, the number of BeiGene shareholders increased by 55.33% to 36,200, while the average circulating shares per person decreased by 35.79% to 3,195 shares [2] - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, up 130.88% year-on-year [2] Institutional Holdings - As of September 30, among the top ten circulating shareholders, China Europe Medical Health Mixed A ranked fourth with 4.6788 million shares, a decrease of 146,600 shares from the previous period [2] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 3.1565 million shares, while other notable changes included a significant reduction in holdings by several funds [2]

Group 1 - On November 11, BeiGene's stock fell by 0.77%, with a trading volume of 734 million yuan [1] - The financing data for BeiGene on that day showed a financing purchase amount of 75.14 million yuan and a financing repayment of 80.40 million yuan, resulting in a net financing outflow of 5.25 million yuan [1] - As of November 11, the total margin balance for BeiGene was 1.36 billion yuan, with a financing balance of 1.34 billion yuan, accounting for 4.20% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of BeiGene shareholders was 23,300, a decrease of 3.90% from the previous period, while the average circulating shares per person increased by 4.11% to 4,976 shares [2] - For the first half of 2025, BeiGene reported a revenue of 17.52 billion yuan, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million yuan, up 115.63% year-on-year [2] - Among the top ten circulating shareholders as of June 30, 2025, China Europe Medical Health Mixed A ranked fourth with 4.83 million shares, an increase of 1.24 million shares from the previous period [2]

Group 1 - On November 6, BeiGene's stock rose by 2.67%, with a trading volume of 767 million yuan [1] - The financing data for BeiGene on the same day showed a financing purchase amount of 88.91 million yuan and a financing repayment of 108 million yuan, resulting in a net financing outflow of 19.39 million yuan [1] - As of November 6, the total margin balance for BeiGene was 1.317 billion yuan, with a financing balance of 1.298 billion yuan, accounting for 4.07% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of BeiGene shareholders was 23,300, a decrease of 3.90% from the previous period, while the average circulating shares per person increased by 4.11% to 4,976 shares [2] - For the first half of 2025, BeiGene reported a revenue of 17.518 billion yuan, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million yuan, up 115.63% year-on-year [2] - Among the top ten circulating shareholders as of June 30, 2025, China Europe Medical Health Mixed A ranked fourth with 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]

Core Viewpoint - BeiGene's stock price has shown significant volatility, with a year-to-date increase of 73.42%, but a recent decline in the short term, indicating potential market fluctuations and investor sentiment changes [1][2]. Group 1: Stock Performance - As of October 20, BeiGene's stock price was 279.24 CNY per share, with a market capitalization of 430.22 billion CNY [1]. - The stock has experienced a 1.73% decline over the last five trading days and an 11.51% decline over the last 20 days, despite a 11.80% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) once, with the last appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A, holding 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选, the sixth largest shareholder, reduced its holdings by 50% to 3 million shares [2]. - 新进股东, 南方中证500ETF, holds 1.7259 million shares, while 香港中央结算有限公司 has exited the top ten shareholders list [2].

Core Viewpoint - BeiGene's stock has shown significant volatility, with a year-to-date increase of 78.46%, but a recent decline over the past five and twenty trading days [1] Group 1: Stock Performance - As of October 16, BeiGene's stock price was 287.36 CNY per share, with a market capitalization of 442.73 billion CNY [1] - The stock experienced a 2.03% increase during the trading session on October 16, with a trading volume of 2.47 billion CNY and a turnover rate of 0.76% [1] - Year-to-date, the stock has risen by 78.46%, but it has decreased by 5.62% over the last five trading days and 9.35% over the last twenty trading days [1] Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03% [2] - The net profit attributable to shareholders for the same period was 450 million CNY, showing a significant increase of 115.63% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of BeiGene's shareholders was 23,300, a decrease of 3.90% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.11% to 4,976 shares [2] - Among the top ten circulating shareholders, notable changes included an increase in holdings by China Europe Medical Health Mixed A and a decrease by Wan Jia You Xuan [2]

Group 1 - The core point of the news is that BeiGene's stock has experienced a decline of 10.81% over the past four days, with a current price of 273.71 CNY per share and a market capitalization of 421.699 billion CNY [1] - BeiGene was founded on October 28, 2010, and went public on December 15, 2021, focusing on the research, development, production, and commercialization of innovative drugs [1] - The company's main revenue source is from drug sales, accounting for 99.10% of total revenue, while collaboration income contributes 0.90% [1] Group 2 - According to data, one fund under Xinda Australia has a significant holding in BeiGene, specifically the Xin'ao New Target Flexible Allocation Mixed A Fund (003456), which held 600 shares, representing 0.12% of the fund's net value [2] - The fund has incurred a floating loss of approximately 6,264 CNY today, with a total floating loss of 19,900 CNY during the four-day decline [2] - The Xin'ao New Target Flexible Allocation Mixed A Fund was established on October 19, 2016, with a current size of 3.261 million CNY and has achieved a year-to-date return of 3.01% [2]